Gao X, Cui Q, Shi X, et al. Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland: a systematic review and meta-analysis. BMC Infect Dis, 2011, 11(1):88.
[28]
Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of
[15]
He Y, Tan SL, Tareen SU, et al. Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A.
[1]
Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med, 1992, 327(27):1899-1905.
[2]
Martins T, Narciso-Schiavon JL, Schiavon LL. Epidemiology of hepatitis C virus infection. Rev Assoc Med Bras, 2007, 57(1):107-112.
[3]
Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol, 2007, 13(17):2436-2441.
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med, 2004, 140(5):346-355.
[10]
Pozzetto B, Bourlet T, Grattard F, et al. Structure, genomic organization, replication and variability of hepatitis C virus. Nephrol Dial Transplant, 1996, 11 supp 4:2-5.
J Virol, 2001, 75(11):5090-5098.
[16]
Ghosh AK, Steele R, Meyer K, et al. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol, 1999, 80(5):1179-1183.
[17]
Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog, 2008, 4(3):e1000032.
[18]
Lemm JA, O'Boyle D, Liu M, et al. Identification of hepatitis C virus NS5A inhibitors. J Virol, 2010, 84(1):482-491.
[19]
Sadler KC, Amsterdam A, Soroka C, et al. A genetic screen in zebrafish identifies the mutants vps18, nf2 and foie gras as models of liver disease. Development, 2005, 132(15):3561-3572.
[20]
Lam SH, Wu YL, Vega VB, et al. Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol, 2005, 24(1):73-75.
[21]
Rekha RD, Amali AA, Her GM, et al. Thioacetamide accelerates steatohepatitis, cirrhosis and HCC by expressing HCV core protein in transgenic zebrafish Danio rerio. Toxicology, 2008, 243(1-2):11-22.
[22]
Amatruda JF, Shepard JL, Stern HM, et al. Zebrafish as a cancer model system. Cancer Cell, 2002, 1(3):229-231.
[23]
Thisse C, Thisse B. High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat Protoc, 2008, 3(1):59-69.
[24]
Her GM, Yeh YH, Wu JL. 435-bp liver regulatory sequence in the liver fatty acid binding protein (L-FABP) gene is sufficient to modulate liver regional expression in transgenic zebrafish. Dev Dyn, 2003, 227(3):347-356.
[25]
Jármay K, Karácsony G, Nagy A, et al. Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol, 2005, 11(41):6422-6428.
[6]
Tsubota A, Fujise K, Namiki Y, et al. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol, 2011, 17(4):419-432.
[7]
Yanagi M, Purcell RH, Emerson SU, et al. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A, 1997, 94(16):8738-8743.
[8]
Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med, 2001, 7(8):927-933.
[9]
Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989, 244(4902):359-362.
[11]
Hidajat R, Nagano-Fujii M, Deng L, et al. Cleavage of the hepatitis C virus NS5A protein by caspase-3 in the interferon sensitivity- determining region in a sequence-dependent manner. Kobe J Med Sci, 2004, 50(5-6):153-166.
[12]
Tan SL, Katze MG. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology, 2001, 284(1):1-12.
[13]
Georgopoulou U, Caravokiri K, Mavromara P. Suppression of the ERK1/2 signaling pathway from HCV NS5A protein expressed by herpes simplex recombinant viruses. Arch Virol, 2003, 148(2):237- 251.
[14]
Park KJ, Choi SH, Choi DH, et al. 1Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2. J Biol Chem, 2003, 278(33):30711-30718.
[29]
Passeri MJ, Cinaroglu A, Gao C, et al. Hepatic steatosis in response to acute alcohol exposure in zebrafish requires sterol regulatory element binding protein activation. Hepatology, 2009, 49(2):443-452.
[26]
Fujino T, Nakamuta M, Yada R, et al. Expression profile of lipid metabolism-associated genes in hepatitis C virus-infected human liver. Hepatol Res, 2010, 40(9):923-929.
[27]
Monazahian M, Böhme I, Bonk S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol, 1999, 57(3):223-229.
[30]
Matthews RP, Lorent K, Mañoral-Mobias R, et al. TNFalpha- dependent hepatic steatosis and liver degeneration caused by mutation of zebrafish S-adenosylhomocysteine hydrolase. Development, 2009, 136(5): 865-875.